A record of what Macquarie Analysis said publicly, with the source. Not advice.
“Bullish on Divi's Laboratories with an 'outperform' rating and a target price of ₹7,400, implying a 26.8% upside. Expects meaningful acceleration in top and bottom line, driven by custom synthesis project scale-up, generic API launches, and operating leverage, with top-line tripling and PAT quadrupling by FY30E from FY24 base.”
Macquarie Analysis’s track record (trackable calls only): 58 graded calls · 95% CI 49–73%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹7,400, as stated.
Window: 12 months, the default when no time frame is stated.
Neither the target ₹7,400 was reached on a close by the end of the window. Miss.
The grader’s working: R4 TARGET_CALL: entered ₹5978.3 on 2025-02-20 (next trading session's close); neither target nor stop reached by window end 2026-02-19. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.